High-Dose Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) Following Allogenic Hematopoietic Stem Cell Transplantation (HSCT) Study

Graft-versus-host Disease Clinical Trial

Official title:
A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) Following Allogenic Hematopoietic Stem Cell Transplantation (HSCT)

Status Recruiting

Clinical Trial Summary

This is a phase I-II clinical trial. Adult subjects with hematological malignancies undergoing allogeneic HSCT from an HLA matched sibling or ≥7 out of 8 allele level HLA matched unrelated donor are eligible for the study if they meet the criteria defined in our standard operation procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria. Subjects will receive a standard of care conditioning regimen. Subjects will receive investigational PTCy, investigational bortezomib and investigational abatacept as GvHD prophylaxis.

Clinical Trial Description

The study will have a phase I and phase II potions. The phase I portion will employ a 3+3 dose escalation design to define the maximum tolerated dose (MTD) of abatacept added to PTCy and bortezomib following HSCT. The phase II portion will consist of two single arm, open label, optimal 2-stage Simon design studies conducted in two separate strata for HLA matched and HLA mismatched donor transplants. Adult patients with hematological malignancies undergoing allogeneic HSCT from an HLA matched sibling or ≥7 out of 8 allele level HLA matched unrelated donor are eligible for the study if they meet the standard criteria defined in our institutional standard operation procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria. Subjects will receive a standard of care conditioning regimen followed by peripheral blood hematopoietic stem cells. Subjects with unrelated donors will also receive rabbit anti-thymocyte globulin (rATG). Subjects will receive investigational PTCy, investigational bortezomib and investigational abatacept as GvHD prophylaxis. The phase II portion dose of abatacept will be the MTD as determined in the phase I portion of the study. In the phase II portions, subjects will be stratified based on whether they receive a matched sibling or matched unrelated (matched) donor transplant and ≥7 out of 8, allele level matched (mismatched) unrelated donor transplant. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05289167
Study type	Interventional
Source	NYU Langone Health
Contact	Emma Futamura
Phone	212-731-6217
Email	emma.futamura@nyulangone.org
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	March 13, 2022
Completion date	December 2026

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01428973` - Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens	Phase 2
Not yet recruiting	`NCT00749164` - Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment	Phase 1/Phase 2
Completed	`NCT00993343` - Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation	Phase 3
Completed	`NCT00360685` - Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX	N/A
Active, not recruiting	`NCT04503616` - Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention	Phase 1/Phase 2
Terminated	`NCT02080195` - Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)	Phase 1/Phase 2
Completed	`NCT02193880` - Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)	N/A
Completed	`NCT02942173` - CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT	Phase 2/Phase 3
Completed	`NCT02145403` - Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies	Phase 1/Phase 2
Recruiting	`NCT01941394` - Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation	Phase 2
Completed	`NCT00141713` - The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease	Phase 2
Recruiting	`NCT01991301` - Carfilzomib for the Prevention of Graft Versus Host Disease	Phase 1
Completed	`NCT00408928` - Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease	Phase 2
Completed	`NCT01633229` - Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications	Phase 1
Completed	`NCT05856058` - To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability	Phase 1
Completed	`NCT02342613` - Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation	Phase 1
Recruiting	`NCT06423131` - Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT	N/A
Completed	`NCT02144025` - Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT	Phase 2
Completed	`NCT01369914` - The Natural History of Graft-Versus-Host Disease in the Eyes
Completed	`NCT00806728` - Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease	Phase 1